Global pharmaceutical company Galderma has received top-line results for its phase 2 study in the US on the efficacy and safety of a single dose of abobotulinumtoxinA versus placebo for the treatment of moderate to severe glabellar lines.
A new study published in Plastic and Reconstructive Surgery has suggested that intradermal botulinum toxin injection, or microbotulinum, is a safe and effective method to treat skin flaws.
According to a report published by Fortune Business Insights, the botulinum toxin market will reach US $8,309 million by 2026, exhibiting a compound annual growth rate of 8%.
Aesthetics reports on today’s update from Parliament
Global pharmaceutical company Galderma’s liquid formulation of botulinum toxin type A has achieved positive results for the treatment of glabellar lines in a phase 2 clinical trial.
A pilot study of 18 male patients has demonstrated an increase in hair density and thickness following botulinum toxin treatment.
We bring you the most up-to-date information for the Aesthetics community across a variety of media, including; news, webinars, podcasts, the Journal, reports, interviews and more!
aesthetics Journal
The Aesthetics Journal is the leading monthly publication for the medical aesthetics specialty. It is peer reviewed and spans an incredible volume of topics. Become a member today to receive the monthly print and digital Journal.
0203 096 1228
2nd Floor, Regal House, 70 London Road
Twickenham TW1 3QS, United Kingdom
© 2023 Easyfairs UK Ltd | Registered in England No. 05067979